THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 81 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2016. The put-call ratio across all filers is 1.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $653,660 | -20.9% | 77,084 | -16.4% | 0.00% | 0.0% |
Q1 2024 | $826,830 | -24.0% | 92,179 | -4.8% | 0.00% | 0.0% |
Q4 2023 | $1,087,906 | +22.2% | 96,790 | -6.2% | 0.00% | 0.0% |
Q3 2023 | $890,308 | -18.6% | 103,166 | -2.3% | 0.00% | 0.0% |
Q2 2023 | $1,093,363 | +116339.1% | 105,639 | +22.1% | 0.00% | 0.0% |
Q1 2023 | $939 | +0.4% | 86,503 | +3.8% | 0.00% | 0.0% |
Q4 2022 | $935 | -99.9% | 83,358 | +3.4% | 0.00% | 0.0% |
Q3 2022 | $818,000 | +20.6% | 80,628 | +7.7% | 0.00% | 0.0% |
Q2 2022 | $678,000 | +12.3% | 74,880 | +18.5% | 0.00% | 0.0% |
Q1 2022 | $604,000 | -12.6% | 63,183 | +1.0% | 0.00% | 0.0% |
Q4 2021 | $691,000 | +53.6% | 62,531 | +2.8% | 0.00% | 0.0% |
Q3 2021 | $450,000 | -46.9% | 60,849 | +4.2% | 0.00% | 0.0% |
Q2 2021 | $848,000 | -32.5% | 58,411 | -5.0% | 0.00% | -50.0% |
Q1 2021 | $1,256,000 | +8.0% | 61,515 | -6.0% | 0.00% | 0.0% |
Q4 2020 | $1,163,000 | +26.7% | 65,432 | +5.4% | 0.00% | +100.0% |
Q3 2020 | $918,000 | -38.3% | 62,057 | -12.4% | 0.00% | -50.0% |
Q2 2020 | $1,487,000 | +3.0% | 70,857 | +13.5% | 0.00% | -33.3% |
Q1 2020 | $1,443,000 | -3.7% | 62,444 | +7.8% | 0.00% | 0.0% |
Q4 2019 | $1,499,000 | +35.5% | 57,916 | +2.0% | 0.00% | +50.0% |
Q3 2019 | $1,106,000 | +18.7% | 56,775 | -0.5% | 0.00% | 0.0% |
Q2 2019 | $932,000 | -25.5% | 57,070 | +3.4% | 0.00% | 0.0% |
Q1 2019 | $1,251,000 | -12.3% | 55,200 | -1.0% | 0.00% | -33.3% |
Q4 2018 | $1,427,000 | +17.9% | 55,783 | +50.6% | 0.00% | +50.0% |
Q3 2018 | $1,210,000 | +34.1% | 37,031 | -6.9% | 0.00% | 0.0% |
Q2 2018 | $902,000 | -2.2% | 39,781 | +4.6% | 0.00% | 0.0% |
Q1 2018 | $922,000 | -14.5% | 38,024 | -1.6% | 0.00% | 0.0% |
Q4 2017 | $1,078,000 | -32.0% | 38,654 | -16.5% | 0.00% | -33.3% |
Q3 2017 | $1,586,000 | -12.8% | 46,318 | +1.5% | 0.00% | -25.0% |
Q2 2017 | $1,818,000 | +12.3% | 45,643 | +3.8% | 0.00% | 0.0% |
Q1 2017 | $1,619,000 | +24.4% | 43,966 | +7.7% | 0.00% | +33.3% |
Q4 2016 | $1,301,000 | -1.9% | 40,824 | +11.6% | 0.00% | -25.0% |
Q3 2016 | $1,326,000 | +71.8% | 36,595 | +7.6% | 0.00% | +100.0% |
Q2 2016 | $772,000 | -1.7% | 34,022 | -18.5% | 0.00% | 0.0% |
Q1 2016 | $785,000 | +38.7% | 41,733 | +20.7% | 0.00% | 0.0% |
Q4 2015 | $566,000 | +53.0% | 34,563 | +2.7% | 0.00% | +100.0% |
Q3 2015 | $370,000 | -10.6% | 33,638 | +5.8% | 0.00% | 0.0% |
Q2 2015 | $414,000 | +3.8% | 31,784 | +38.3% | 0.00% | 0.0% |
Q1 2015 | $399,000 | +32.6% | 22,974 | +13.7% | 0.00% | 0.0% |
Q4 2014 | $301,000 | -33.0% | 20,199 | +3.7% | 0.00% | 0.0% |
Q3 2014 | $449,000 | -32.6% | 19,474 | -6.7% | 0.00% | -50.0% |
Q2 2014 | $666,000 | – | 20,881 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |